Hyundai Bioland KRX:052260KOSDAQ
현대바이오랜드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked4since Sep 11
In Q2 2026, Hyundai Bioland reported revenue of ₩40.3bn, up 16.4% year on year, and operating profit of ₩7.0bn. Hyundai Bioland (현대바이오랜드) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Revenue & profit growth Screener
Hyundai Bioland quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩40.3bn | +16.4% | ₩7.0bn margin 17.5% | ₩6.0bn |
| Q1 2026 | ₩38.2bn | +13.5% | ₩5.2bn margin 13.6% | ₩5.2bn |
| Q4 2025 derived | ₩26.7bn | +24.3% | −₩2.5bn margin −9.3% | −₩1.8bn |
| Q3 2025 | ₩35.5bn | +5.9% | ₩4.7bn margin 13.3% | ₩3.9bn |
| Q2 2025 | ₩34.6bn | +5.4% | ₩5.5bn margin 15.9% | ₩5.1bn |
| Q1 2025 | ₩33.7bn | +17.0% | ₩5.0bn margin 14.8% | −₩7.0bn |
| Q4 2024 derived | ₩21.5bn | +18.3% | ₩2.8bn margin 12.9% | −₩5.2bn |
| Q3 2024 | ₩33.5bn | +24.0% | ₩3.4bn margin 10.2% | ₩3.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Hyundai Bioland top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.